Elastic NV vs Revvity Inc — how do they compare? Elastic NV trades at $77.12 (market cap $7.94B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.24% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| ESTC | RVTY | |
|---|---|---|
Market Cap | $7.94B | $12.91B |
Sector | Technology | Technology |
52-Week High | $94.47 | $117.75 |
52-Week Low | $43.30 | $82.26 |
Enterprise Value | $7.16B | $15.23B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $76.64, up 0.42% today, with a bullish technical outlook as it trades above key moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.61 exceeding the $0.561 estimate. Recent news highlights include a collaboration with OpenAI and recognition as a leader in Gartner's Magic Quadrant for Observability Platforms. Revenue growth is robust, projected to rise from $1.48B in 2025 to $1.7B in 2026, while net income is expected to turn positive at $368M.
The stock offers growth potential driven by AI partnerships and market leadership, but faces risks from high valuation multiples like a P/E of 22.26 and EV/EBITDA of 206.43. Analyst consensus is bullish with a $74.21 price target and no sell ratings, though RSI levels indicate overbought conditions. Key risks include competitive pressures and reliance on tech sector demand.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Trailing returns across standard periods
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →